Cancer cells are long known to exhibit increased aerobic glycolysis, but glycolytic inhibition has not offered a viable chemotherapeutic strategy in part due to the systemic toxicity of antiglycolytic agents. However, recent studies suggest that a combined inhibition of glycolysis and mitochondrial function may help overcome this issue. In this study, we investigated the chemotherapeutic efficacies of mitochondria-targeted drugs (MTDs) in combination with 2-deoxy-D-glucose (2-DG), a compound that inhibits glycolysis. Using the MTDs termed Mito-CP and Mito-Q we evaluated relative cytotoxic effects and mitochondrial bioenergetic changes in vitro. Interestingly, both Mito-CP and Mito-Q synergized with 2-DG to decrease ATP levels in two cell lines. However, with time, the cellular bioenergetic function and clonogenic survival were largely restored in some cells. In a xenograft model of human breast cancer, combined treatment of Mito-CP and 2-DG led to significant tumor regression in the absence of significant morphological changes in kidney, liver, or heart. Collectively, our findings suggest that dual targeting of mitochondrial bioenergetic metabolism with MTDs and glycolytic inhibitors such as 2-DG may offer a promising chemotherapeutic strategy.
INTRODUCTION
Emerging research in cancer chemotherapy is focused on exploiting the biochemical differences between cancer cell and normal cell metabolism (1, 2) . One of the fundamental changes that occurs in most malignant cancer cells is the shift in energy metabolism from oxidative phosphorylation to aerobic glycolysis to generate ATP (the Warburg effect) (3) (4) (5) . Several agents that specifically inhibit glycolytic metabolism have been used as effective anticancer agents in cellular systems and in animal models (5, 6 ).
However, this approach has yielded fewer positive results in human patients (with the exception of imatinib), most likely due to dose-limiting side effects (e.g., neurotoxicity) (7) . One of the most frequently used anti-glycolytic agents is 2-deoxy-D-glucose which is phosphorylated by hexokinase and subsequently inhibits ATP generated via the glycolytic pathway (7, 8) . However, high concentrations (~20 mM) of 2-DG were typically used to inhibit the glycolytic metabolism in cancer cells (9) . 2-DG is undergoing clinical trials for treatment of glioma and its efficacy is limited by the systemic toxicity (10) . A recent strategy to "hypersensitize" tumor cells involved the combined use of mitochondrial inhibitors (oligomycin and antimycin) or delocalized cationic compounds with 2-DG (11, 12) . Dual targeting of mitochondrial and glycolytic pathways was suggested as a promising chemotherapeutic strategy (13, 14) . 4 an attractive experimental chemotherapeutic strategy. Previously, investigators have used agents (e.g., rhodamine-123, rotenone, antimycin, or oligomycin) that inhibit mitochondrial oxidative phosphorylation in combination with glycolytic inhibitors to eradicate tumor cells (19) . In contrast, a similar treatment (rhodamine-123 and 2-DG) failed to elicit cytotoxic effects in normal epithelial cells (20) . The rationale for this approach is that compromised oxidative phosphorylation in tumor cells leads to stimulation of glycolytic metabolism for ATP generation. Dichloroacetate (DCA), a pyruvate mimetic that inhibits pyruvate dehydrogenase kinase, shifts cellular metabolism from glycolysis to OXPHOS (21, 22) . However, DCA was selectively more toxic in cells with defective mitochondrial electron transport chain (22, 23) . As indicated earlier, mitochondrial targeting of drugs combined with 2-DG or other glycolytic inhibitors may be an extremely effective strategy to eliminate slow growing hypoxic tumor cells present in most solid tumors (12) .
The accumulation of mitochondria-targeted delocalized lipophilic cations such as Mito-CP ( Fig. 1 ) in tumor cells is controlled by several factors including the lipophilicity and the chain length of MTDs, the negative mitochondrial membrane potential, and the levels of p-glycoprotein mediated multidrug resistance (MDR) protein that actively pumps cationic drugs out of the tumor cells (24) . Recent research showed that Mito-Q (coenzyme-Q conjugated to an alkyl triphenylphosphonium cation) and Mito-CP (a fivemembered nitroxide, CP, conjugated to a TPP + ) potently inhibited proliferation of breast cancer cells (MCF-7 and MDA-MB-231) or human colon cancer cells (HCT-116) (25, 26) . These mitochondria-targeted drugs (MTDs) did not significantly affect normal cell proliferation (25) . In related studies, we have shown that the MTDs effectively mitigated the toxic side effects (cardiotoxicity or nephrotoxicity) induced by conventional chemotherapeutics such as doxorubicin or cis-platin (27) . These results led us to postulate the following hypothesis: The combined use of MTDs (Mito-CP and Mito-Q) and 2-DG will synergistically enhance cytotoxicity selectively in cancer cells compared to either drug alone. In this study, we investigated the chemotherapeutic effects of 2-DG in combination with Mito-CP, Mito-Q, and other appropriate control compounds. Results from this study indicate that targeting mitochondria with small molecular weight antioxidants conjugated to an alkyl TPP + and glycolytic inhibitors is a potentially promising and effective cancer treatment strategy.
MATERIALS AND METHODS

Chemicals
Mito-CP and Mito-Q were synthesized as previously published (28,29) (see Fig. 1 6 grown at 37°C in 5% CO 2 . MCF-7 cells were maintained in MEM-Į (Invitrogen) containing 10% fetal bovine serum, bovine insulin (10 ȝg/ml), penicillin (100 U/ml) and streptomycin (100 ȝg/ml). MCF-10A cells were cultured in DMEM/F12 media (1:1) (Invitrogen) supplemented with 5% horse serum, bovine insulin (10 ȝg/ml), epidermal growth factor (20 ng/ml), cholera toxin (100 ng/ml), and hydrocortisone (0.5 ȝg/ml), penicillin (100 U/ml) and streptomycin (100 ȝg/ml). MDA-MB-231 cells were cultured in DMEM, 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 ȝg/ml). The MDA-MB-231-luc cell line stably transfected with luciferase was cultured under the same conditions as the MDA-MB-231 cells described above. These cells were a kind gift from Dr. Michael B. Dwinell (Department of Microbiology and Molecular Genetics, Medical College of Wisconsin), and were recently described in detail (30) . They are regularly assessed for standard growth characteristics, and tumorigenicity in nude mice.
Extracellular flux assay
The bioenergetic function of MCF-7 and MCF-10A cells in response to Mito-CP or 2-DG was determined using a Seahorse Bioscience XF24 Extracellular Flux Analyzer (34) . After 4 weeks of treatment, the mice were sacrificed, and the tumor, kidney, heart and liver were removed and formalin fixed. These tissues were then paraffin embedded and stained with hematoxylin and eosin (H&E).
Statistics
All results are expressed as mean ± SEM. Comparisons among groups of data were made using a one-way ANOVA with Tukey's post hoc analysis. P value of <0.05 was considered to be statistically significant. obtained under various experimental conditions following Mito-CP and 2-DG treatments were determined according to the procedures outlined previously (31, 32) . As shown in Figure 2A and B, addition of Mito-CP (1 μM) greatly decreased the OCR in both MCF-7 and MCF-10A cells. Notably, Mito-CP stimulated ECAR levels in both MCF-7 and MCF-10A cells, signaling an increase in glycolysis likely to compensate for the loss of OCR.
RESULTS
Effects of Mito-CP or
As expected, 2-DG (5 mM) that inhibits glycolysis decreased the ECAR by 40% (Fig. 2C and D). Under these conditions, individual treatment with either Mito-CP, or 2-DG slightly but significantly decreased the intracellular ATP levels in MCF-7 cells, but not in MCF-10A cells ( Fig. 2E and F) . Bioscience culture plates. One hour prior to the start of the experiment, the media was changed in all wells to a specialized DMEM-based assay media lacking glucose and FBS. Baseline ECAR was measured, and then glucose was injected to a final concentration of either 5.5 or 17.5 mM to match routine culture conditions for each cell type ( Supplementary Fig. 1B ). This resulted in a stimulation of ECAR that was not significantly different between cell types or glucose concentrations (Supplementary Fig.   1B ). Oligomycin was subsequently injected to a final concentration of 1 μg/ml in all Fig. 2A and B) . Similar results were observed in another breast cancer 
cell line, MDA-MB-231 ( Supplementary Fig. 3A and B) . Notably, the enhancement of ATP depletion is not related to the delocalized cation only, as Me-TPP + did not sensitize the cells to 2-DG ( Supplementary Fig. 2 ). These results indicate that MTDs (Mito-CP and Mito-Q) with an antioxidant moiety (nitroxide group and Co-Q) conjugated to the TPP + group via a long aliphatic carbon chain greatly potentiate ATP-depleting activity of 2-DG in MCF-7 cells.
Cytotoxic effects of Mito-CP or Mito-Q in combination with2-DG in MCF-7 and
MCF-10A cells
We measured the cytotoxicity after a 6 h and 24 h treatment of MCF-7 and MCF-10A
with either Mito-CP (1 μM), Mito-Q (1 μM) or Dec-TPP + (1 μM) and varying concentrations of 2-DG under the same experimental conditions as in Figure 3 . The cytotoxicity data obtained by monitoring Sytox Green dye uptake normalized to the total number of cells and are shown in Figure 4 . All three compounds caused a slight increase in 2-DG cytotoxicity in MCF-7 cells after a 6 h treatment (Fig. 4A ) that was markedly increased after a 24 h treatment (Fig. 4B ). Combined treatment with 2-DG and either Mito-CP or Mito-Q caused a more dramatic increase in cytotoxicity in MCF-7 cells compared to MCF-10A cells ( Fig. 4B and D) . In contrast, Dec-TPP + (that was devoid of nitroxide or Co-Q moiety) was equally toxic in MCF-7 and MCF-10A cells in the presence of 2-DG ( Fig. 4B and D) . Similar trends were observed with regard to cell viability, as measured by the cell's ability to reduce resazurin to resorufin. There was a modest decrease in cell viability (30-40%) after a 6 h treatment with Mito-CP (1 μM),
Mito-Q (1 μM), or Dec-TPP + (1 μM) with varying levels of 2-DG in MCF-7 or MCF-10A Supplementary Fig. 4A-D) . However, after a 24 h treatment, Mito-CP and Mito-Q decreased the viability of MCF-7 cells to a much greater extent as compared to MCF-10A cells ( Supplementary Fig. 4B and D) . These results are consistent with the cytotoxicity results (Fig. 4) . The glucose concentration in the media used for MCF-7 and MCF-10A cells was different (5.56 mM vs. 17.5 mM). Therefore, we tested the effects of 2-DG at different concentrations. Notably, 2-DG (5 and 20 mM) did not significantly affect the colony formation, or cell death in MCF-10A cells (Fig. 4 and 5 ). Furthermore, we tested the cytotoxicity in MCF-7 cells cultured in media containing 17.5 mM glucose (same as in MCF-10A cells). Notably, combined treatment with 2-DG and Mito-CP for 24 h still caused a more dramatic increase in cytotoxicity in MCF-7 cells compared to MCF-10A cells (Fig. 4B, D and Supplementary Fig.5 ). In addition, the combined treatment with Mito-CP and 2-DG elicited greater cell death and decreased colony formation in MCF-7 cells, even when 2-DG was used at recommended glucose concentrations in the media for each cell type (5 mM in MCF-7 vs. 20 mM in MCF-10A).
Incubation with the untargeted nitroxide CP or Me-TPP + with different 2-DG levels did not significantly increase cytotoxicity of 2-DG in either cell line even after a 24 h treatment ( Supplementary Fig. 6 ).
Effects of Mito-CP, Mito-Q, or Dec-TPP + and 2-DG on MCF-7, MDA-MB-231 and
MCF-10A cell proliferation: Clonogenic analyses
One of the hallmarks of tumor cells is the ability to form colonies (33) . As shown in 
Effects of Mito-CP and Mito-Q alone and in combination with 2-DG on mitochondrial bioenergetic function in MCF-7 and MCF-10A cells
Although treatment with Mito-CP and Mito-Q in the presence of 2-DG dramatically decreased intracellular ATP levels in both MCF-7 and MCF-10A cells, the clonogenic survival analysis showed that this treatment selectively inhibited survival in MCF-7 to a much greater extent than in MCF-10A cells. This suggested that MCF-10A cells were able to recover from the combination treatment (mitochondrial and glycolytic inhibitors) whereas the MCF-7 cells failed to recover under the same conditions. To investigate this process in more detail, we monitored the mitochondrial bioenergetic function in MCF-7 and MCF-10A cells using the XF24 extracellular flux analyzer. The protocol for this experiment is shown in Supplementary Figure 7 . As shown, both cell lines were treated with Mito-CP, Mito-Q, and 2-DG for 6 h followed by washout of the treatments, and returned to fresh culture media. After 36 h, OCR was measured and the effects of adding oligomycin, FCCP, and antimycin A were determined (Fig. 6A-D) . The use of these metabolic modulators allows determination of multiple parameters of mitochondrial function. Interestingly, the most dramatic effect of Mito-CP was on basal OCR and the OCR linked to ATP production (Fig. 6E) . These parameters were calculated from the traces in Fig. 6A-D (31,32) . Notably, inhibition of OCR was persistent 36 h after removal of Mito-CP in MCF-7 cells, but not in MCF-10A cells. Mito-Q had a similar effect on mitochondrial function, although the degree of inhibition was markedly lower. The effects of Mito-CP and Mito-Q were also examined immediately after 6 h treatment with these compounds (Supplementary Fig. 8 ). Consistent with the data shown in Figure 2 , after a 6 h exposure to either Mito-CP or Mito-Q, mitochondrial oxygen consumption was decreased. Curiously, the effect of these compounds was more dramatic in MCF-10A cells as compared to MCF-7 cells. Paired with the data in Figure 6 , this suggests that MCF-10A cells are more adept at recovering from inhibition of mitochondrial function than MCF-7 cells. These data also show that the effect of 2-DG is not persistent after removal. As shown in Fig. 6E , this inhibition was reversed 36 h after removal of the 2-DG. Additionally, we found that inhibition of OCR persisted up to 60 h after washout of Mito-CP or Mito-Q. As shown in Supplementary Fig. 9 , the mitochondrial function was similarly inhibited after 60 h following washout. Inhibition of mitochondrial function was persistent in MCF-7 cells but not in MCF-10A cells.
Collectively, these data suggest that the mechanism for selective killing of MCF-7 cells when co-treated with 2-DG and MTDs is through irreversible mitochondrial inhibition. We investigated the effects of the combined use of Mito-CP and 2-DG in an in vivo breast tumor model. Administration of 2-DG or Mito-CP alone had little or no effect on the rate of tumor growth in the xenograft mouse model (Fig. 7A) . In contrast, the combined treatment of Mito-CP and 2-DG led to a significant decrease in the bioluminescence signal intensity (total flux) as compared to the control mice after 3 and 4 weeks of treatment ( Fig. 7A and B) . Furthermore, this combined treatment (Mito-CP plus 2-DG) for 4 weeks significantly diminished tumor weight (Fig. 7C) without causing any significant changes in kidney, liver and heart weight or other major morphological changes (as determined by H&E staining in Supplementary Fig. 10 and Table 1 .)
Effects of Mito
DISCUSSION
Previous research has shown that mitochondrial targeting of antioxidants could inhibit tumor cell proliferation (25, 26) . Delocalized phosphonium cations were shown to exert antitumor activity in several tumor cell lines (35, 36) . For example, it was recently reported that Mito-CP but not CP induced an increase in phosphorylated ERK1/2 in colon cancer cells (25) . Furthermore, the selective toxicity of mitochondria-targeted vitamin-E succinate conjugated to TPP + in tumor cells was attributed to enhanced mitochondrial localization and binding to complex 2 of the mitochondrial respiratory chain (37) . In other studies, selective targeting of tumor-specific cellular energy metabolism synergistically exacerbated cytotoxicity in cancer cells treated with antiglycolytic agents or with inhibitors of fatty acid β-oxidation (38) . A metabolic shift to glycolysis occurs during anti-angiogenic therapy with drugs (e.g., bevacizumab) that block vascular endothelial growth factor in glioblastoma (39) . Upregulation of the proliferation. In contrast, Decyl-TPP + did increase cell death (Fig. 4) , though the specificity for cancer cells was notably lost. The molecular target involved in enhancing the cytotoxic effects of TPP + -substituted compounds in tumor cells is presently unknown, nor do we fully understand the mechanism(s) by which Mito-CP and Mito-Q preferentially inhibit tumor cell proliferation.
The most salient difference between the response of MCF-7 and MCF-10A cells to
MitoCP is in the stimulation of glycolysis in response to inhibition of mitochondrial oxygen consumption (Fig. 2) . MCF-10A cells have a higher apparent ability to stimulate 
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ECAR, indicating increased glycolytic function in response to Mito-CP. It is likely that this stimulation of glycolysis is better able to support ATP production in MCF-10A cells, as compared to MCF-7 cells (Fig. 2) . Maintenance of ATP levels early in the treatment with Mito-CP suggests that the cells are better able to survive co-treatment with 2-DG.
This may happen despite a loss of ATP in both cell lines when co-treated with Mito-CP and 2-DG (Fig. 3) . It is also worth noting that mitochondrial oxygen consumption and glycolysis both recover more completely in MCF-10A cells as compared to MCF-7 cells (Fig. 6 ). This resilience likely underpins the preferential cytotoxicity of MitoCP and 2-DG cotreatment in MCF-7 cells both in vitro (Fig. 5 ) and in vivo (Fig. 7) .
MDR-1 or p-glycoprotein, the product of the MDR1 gene, is a multi-drug transporter.
Elevated levels of MDR-1 in cancer cells, therefore, antagonize the proapoptotic effects of anticancer drugs, rendering these cells resistant to apoptosis (42) . Currently, the affinity of Mito-CP to p-glycoprotein mediated MDR recognition is not known. Previously, it was reported that simple nitroxides (e.g., Tempol) inhibit efflux of p-glycoprotein- In summary, we report in this study that the combined use of a mitochondriatargeted antioxidant that is relatively nontoxic to normal cells and an anti-glycolytic agent (e.g., 2-DG) synergistically enhanced the cytotoxic potential in breast tumor cells.
As has been demonstrated in earlier publications (26, 28) , an added value of this adjuvant therapy is the potential cytoprotective ability of MTDs (e.g., Mito-CP and Mito-Q) against conventional chemotherapy-induced mitochondrial oxidative damage in normal cells, thereby increasing the overall therapeutic index.
Supplementary information is available at the Cancer Research website. 
